Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
2.703
+0.153 (6.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
Galmed Pharmaceuticals Employees
As of December 31, 2023, Galmed Pharmaceuticals had 8 total employees, including 3 full-time and 5 part-time employees. The number of employees decreased by 2 or -20.00% compared to the previous year.
Employees
8
Change (1Y)
-2
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$790,500
Market Cap
4.07M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
GLMD News
- 5 months ago - Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PRNewsWire
- 5 months ago - Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases - PRNewsWire
- 11 months ago - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 - PRNewsWire
- 1 year ago - Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis - PRNewsWire
- 1 year ago - Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study - PRNewsWire
- 1 year ago - Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis - PRNewsWire
- 1 year ago - Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 1 year ago - Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering - PRNewsWire